Antibody-mediated rejection (AMR) treatment involves the use of therapies that help prevent the human body from rejecting transplanted organs by blocking antibodies that attack the transplant. AMR therapies work by suppressing the immune system's response to the transplanted organ, allowing the organ to function properly. Commonly used AMR therapies include plasma exchange, intravenous immunoglobulin (IVIg), anti-thymocyte globulin (ATG), bortezomib, eculizumab, belatacept and caplacizumab.

 The antibody-mediated rejection market is estimated to be valued at USD 126.5 Mn in 2024 and is expected to reach USD 291.1 Mn by 2031, growing at a compound annual growth rate (CAGR) of 12.64% from 2024 to 2031.

Key Takeaways



Key players operating in the antibody-mediated rejection treatment market are Alexion Pharmaceuticals, Sandoz, Teva Pharmaceuticals Industries, Sanquin, Hansa Medical, and XENOTHERA. These players are focusing on developing novel biological therapies for preventing AMR and improving long-term outcomes of solid organ transplants.



The growing solid organ transplant procedures worldwide along with increasing awareness about AMR and availability of its treatment options present significant growth opportunities in the market. Furthermore, companies are investing heavily in research focusing on development of monoclonal a Antibody-mediated Rejection and other biological therapies to treat AMR more effectively.



Technological advancements such as development of novel biomarkers for early detection of AMR and vaccination therapy are also expected to boost the market growth. Biomarkers enable detection of AMR at a pre-clinical stage allowing timely intervention while vaccination aims to prevent antibody formation against transplant altogether.



Market Drivers



One of the key drivers for the antibody-mediated rejection treatment market is the increasing incidence of organ failure cases worldwide requiring transplantation. Conditions like cardiovascular disease, liver cirrhosis and kidney failure are on rise driving the need for solid organ transplants. As transplants increase so does the risk of complications like AMR. Currently, there is an acute shortage of donor organs compared to demand driving development of newer therapies.


Challenges in the Antibody-mediated Rejection Market



There are several challenges faced in the antibody-mediated rejection market. Some of the major ones include lack of proper diagnosis, high cost of treatment and lack of awareness. Antibody-mediated rejection is difficult to diagnose accurately as the symptoms are similar to other transplant complications. This delays the start of proper treatment. The treatment of antibody-mediated rejection requires advanced immunosuppressant medications which are often very expensive. This poses affordability challenges. There is also lack of awareness about this medical condition among patients as well as medical professionals. This leads to under diagnosis of the condition. Some patients may not receive appropriate treatment in the initial stages due to lack of proper diagnosis. Overall, early and accurate diagnosis along with cost-effective treatment options remain important challenges.



SWOT Analysis



Strength: Growing research activities to develop new diagnostic tools and treatment therapies. Advancement in transplant procedures and postoperative care protocols have also improved outcomes.



Weakness: High cost of current antibody-mediated rejection treatments limits widespread access and adoption. Lack of awareness about this medical condition exists even among healthcare professionals in some regions.



Opportunity: Increasing organ transplantation volumes worldwide presents scope for growth. Spreading awareness can help improve diagnosis rates. Development of new affordable treatment alternatives also offers business opportunities.



Threats: Stringent regulatory norms for transplant drugs and devices add compliances cost burden. Risk of new mutations in viruses and other pathogens pose challenges.



The North American region accounts for the largest share in the antibody-mediated rejection market in terms of value owing to high healthcare spending and availability of advanced treatment options. The Asia Pacific region has emerged as the fastest growing market driven by rising organ transplantation and increasing healthcare investments in major Asian countries. Countries like China, India and Japan are generating significant demand.

Get this Report in Japanese Language: 抗体介在性拒絶反応市場

Get this Report in Korean Language: 항체 매개 거부 시장

Author Bio:

Alice Mutum is a seasoned senior content editor at Coherent Market Insights, leveraging extensive expertise gained from her previous role as a content writer. With seven years in content development, Alice masterfully employs SEO best practices and cutting-edge digital marketing strategies to craft high-ranking, impactful content. As an editor, she meticulously ensures flawless grammar and punctuation, precise data accuracy, and perfect alignment with audience needs in every research report. Alice's dedication to excellence and her strategic approach to content make her an invaluable asset in the world of market insights.

(LinkedIn: www.linkedin.com/in/alice-mutum-3b247b137 )